On March 10, 2023, the Board of Directors of Histogen Inc. approved removing the interim title of Steven J. Mento, Ph.D. as the President of the Company, the Board appointed Daniel L. Kisner, M.D. as the Non-Executive Chairman of the Board and eliminated the positions of Executive Chairman, formerly held by Dr. Mento, and Lead Independent Director, formerly held by David H. Crean, Ph.D. In connection with Dr. Mento's status as President, the Company entered into an amendment and restatement of his executive employment agreement pursuant to which he is entitled to twelve (12) months' severance, including target bonus, and reimbursement of COBRA premium reimbursement in the event of a termination without cause or termination by Good Reason which such severance and COBRA reimbursement is increased to eighteen (18) months in the event of a termination after a change of control event. The CEO Agreement also provides for accelerated vesting of certain of his outstanding options in the event of termination in connection with a change in control.